The difficulties in managing multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB are well known. The regimens are very expensive, often toxic, and require up to 24 months to achieve an acceptable probability of success [1–3].
The first nationwide report on the drug resistance profile of the drugs composing the WHO “shorter” regimen in Brazil http://ow.ly/XfJa3096FsT
Conflict of interest: None declared.
- Received November 24, 2016.
- Accepted January 9, 2017.
- Copyright ©ERS 2017